Personalized medicine – the idea of giving patients with treatments that are more effective and have fewer side effects – has been regarded as the greatest opportunity for the health-care system in recent years. In the meanwhile, for some therapies, this has already become a reality. However, because the necessary knowledge and technological foundation is still being developed, just a few applications, products, and services have been commercialized to date. Furthermore, current reimbursement practices, approval procedures, and medical professionals continue to favor traditional drugs. A large-scale implementation of personalized medicine necessitates a shift in the health-care system in general, as well as the pharmaceutical and life-science businesses in particular. While the economic importance of product innovations has long been recognized and encouraged, the focus over the last three decades has shifted to services and product-service systems.
Title : The role of ATP as a Hydrotrope in health and disease
Jack V Greiner, Harvard Medical School, United States
Title : Precision treatment of alzheimer's
Boris Tankhilevich, Magtera, Inc., United States
Title : Modeling competition between subpopulations with variable DNA content in resource limited microenvironments
Noemi Andor, H. Lee Moffitt Cancer Center & Research Institute, United States
Title : Progesterone receptor pathways in preterm birth
Beverlee Wood, Case Western Reserve University, United States
Title : The use of anti seizure medication therapeutic blood level determination to personalise the treatment of epileptic seizures especially in patients attending the accident and emergency department
Roy Gary Beran, University of New South Wales, Australia
Title : Monitoring folds localization in ultra-thin transition metal dichalcogenides using Optical Harmonic Generation
Ahmed Raza Khan, Australian National University, Australia